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In April 2003, 50 years after Watson and Crick first
described the chemical structure of DNA [1], the DNA
sequence that makes up the human genome was proclaimed
“essentially complete” [2]. Following on from this, in
October 2005, the project of the HapMap consortium to
identify the locations of one million common single-
nucleotide polymorphisms (SNPs) in the context of this ref-
erence human genome sequence were completed [3].
Accomplishing these two genomic milestones required the
development, testing and implementation of technology
platforms that could produce data at previously unprece-
dented throughputs, as well as of the bioinformatics tools
and computational capabilities to analyze the resulting data
and to interpret it in meaningful ways. It is this critical inter-
play of technology and bioinformatics that will usher in the
next era of genome sequencing technology, commonly
referred to as ‘the $1,000 genome’  on the basis of its tar-
geted price per genome in US dollars; today, we find our-
selves poised at the brink of this era. In this paradigm, the
cost of determining an individual genome sequence would
fall to a price of around $1,000, placing it firmly in the realm
of advanced clinical diagnostic tests. As a result, determining
a person’s genome sequence might ultimately become an
important first step upon entering a health insurance
network or a health care provider’s practice, akin to deter-
mining their height, weight and blood type, for example. 
Why aim for a $1,000 genome? 
Given this paradigm, one might ask why a $1,000 genome is
an important or necessary goal to achieve. Fundamentally,
even with the significant achievements of the HapMap Project
[3], we have little context for comprehending the breadth of
human genomic diversity, encompassing all types of variation
beyond common single-nucleotide variants. Capturing this
range of diversity, at the current cost of around $10-20 million
per genome sequence, places it firmly outside the bounds of
fiscal reality. Yet without this ‘baseline’, genome scientists and
statisticians lack a contextual framework within which to eval-
uate the genome-characterization projects that are presently
under consideration. Some such projects are described here. 
As recently outlined by Hartwell and Lander [4], the com-
prehensive characterization of all differences in DNA
sequence and chromosome organization between cancer
genomes and their corresponding normal genomes should
have a significant impact on our understanding of the spec-
trum of genomic alterations that underlie malignancy.
Similar projects are currently being championed by the
National Human Genome Research Institute [5] to provide
sequencing and analysis of focused regions in the genomes
of individuals with mapped, uncloned, autosomal Mendelian
disorders, X-linked disorders and specific common diseases.
These and similar projects require a comprehensive combi-
nation of focused genome re-sequencing that targets specific
‘suspect’ genes, a characterization of chromosomal amplifi-
cations and/or deletions, comprehensive gene-expression
profiling, and karyotyping, when possible. Taken together,
this broad-brush approach will potentially further our
understanding of a particular disease, with genome- and
transcriptome-level characterizations that identify the
shared somatic changes associated with the phenotype. 
Abstract
A new generation of DNA-sequencing platforms will become commercially available over the next
few years. These instruments will enable re-sequencing of human genomes at a previously unimagined
throughput and low cost. Here, I examine why the $1,000 human genome is an important goal for
research and clinical diagnostics, and what will be required to achieve it.Projects such as these are ‘discovery’ efforts: they aim to
characterize a relatively small (typically not statistically sig-
nificant) number of affected individuals or samples, first
evaluating genome alterations for each individual and then
establishing shared, statistically significant somatic alter-
ations for the group. A subsequent phase would follow these
discovery efforts that would aim to evaluate the genome
alterations ascertained from the smaller group in thousands
of similar samples, using high-throughput, inexpensive
assays that can provide the necessary statistical power to
establish (or refute) the contribution of each mutation. Ulti-
mately, this approach will yield genome-wide sequence-
based biomarkers; the mutations, copy-number changes,
rearrangements and other alterations that are diagnostic for
the disease in question. With knowledge of these biomarkers
in hand, the availability of rapid and inexpensive human
genome re-sequencing (so-called as the reference sequence
is already known) heralds an era in which re-sequencing
becomes a clinical diagnostic or prognostic tool.
The technologies currently available 
Placing the task of developing a $1,000 genome technology in
context requires a quick overview of the current state of the art
in genome re-sequencing technology. There are already
several commercial platforms that can evaluate known human
SNPs in a rapid and massively parallel manner, including
those offered by Illumina [6] and Affymetrix [7]. These tech-
nologies predominately use DNA:DNA hybridization and are
ideal for genotyping known SNPs and identifying copy-
number differences, but are unsuitable for discovery of novel
SNPs or other polymorphisms (insertions or deletions -
‘indels’ - or rearrangements). For novel polymorphisms, DNA
sequencing of products obtained by PCR from genomic DNAs,
using primers designed to match selected regions of the refer-
ence human genome, represents the best technology to date. A
PCR-based re-sequencing approach has limitations but has
been implemented by brute force for several large-scale
projects [8-13]. 
In many ways, this situation is somewhat reminiscent of the
early days of large-scale genome sequencing, in that many of
the components for automation, methodology and bioinfor-
matics are, in my opinion, being developed in a ‘just-in-time’
fashion. We should hope, however, to be saved from this
path because PCR-based re-sequencing of the human
genome is ultimately limited by several factors. Selecting
unique primers for every region of interest in the human
genome is frankly not possible, because of SNPs and/or
repetitive content that reduce the stability of primer-
annealing sites near exons, and because of gene families and
pseudogenic regions. Even when unique primers can be
designed, data-quality issues frequently arise in PCR and/or
sequencing as a result of structural features (high GC
content or homopolymer and dinucleotide runs). Further-
more, the overall cost of PCR-based re-sequencing is about
2.5 times that of clone-based sequencing, primarily because
of the expense of PCR compared with high-throughput sub-
clone isolation. This cost, coupled with a higher inherent
failure rate for PCR from genomic DNA templates, further
increases re-sequencing costs and timelines, as either more
patients must be sequenced to achieve mutation discovery
across samples, or additional attempts at PCR and sequenc-
ing of fewer samples must be successfully completed to
obtain the necessary data. 
The technology needed to reduce the cost of
genome sequencing 
What, then, are the general features of a technology platform
that can overcome the inherent limitations of our PCR-based
re-sequencing paradigm and deliver a genome for signifi-
cantly less cost and within a much faster time frame than at
present? We can examine a generic de novo sequencing
pipeline for clues (Figure 1a). One of the least automated and
most error-prone steps at present is preparation of genomic
subclone libraries. An ideal re-sequencing platform would
therefore remove the sub-cloning step and sequence directly
from a relatively small input quantity (several micrograms,
for example) of genomic DNA. A side benefit of skipping
conventional sub-cloning is that cloning bias, which can
skew representation of a genome, is avoided (which is not to
say that other types of bias might not be introduced).
Another significant benefit is that subsequent clone-specific
steps, such as picking clones from agar plates, isolation of
individual subclone DNAs and sequencing reactions in
microtiter plates, are eliminated along with much of the
automation required to perform them. Contrast the more
complex workflow in Figure 1a to a generic massively paral-
lel instrument workflow in Figure 1b, for example.
Massively parallel data production in a single duty cycle of an
instrument is another critical component for success, and the
amount of data required to be produced depends solely on the
size of the genome. Currently, a capillary sequencing instru-
ment produces around 1.35 megabases (Mb) of sequence per
24-hour duty cycle (20 x 96 samples daily at an average read
length of 700 bases), which means that about 4,500 duty
cycles are needed to produce the raw base equivalent of a
diploid human genome (I estimate roughly 12 years). By con-
trast, each ‘$1,000 genome’ instrument should require about a
month per diploid genome of raw data, in order to provide a
suitable ‘discovery’ research platform (more realistically 1-5
days per genome would be required, once whole-genome re-
sequencing moves into the clinical laboratory). 
Specifications for the accuracy of base-calling, the length of
sequence reads and the ability to produce sequence from the
paired ends of each DNA fragment are equally critical. For re-
sequencing, unequivocal placement of a read pair onto the ref-
erence genome and determining whether the fragment ends,
so aligned, encompass a region of ‘difference’ (for example a
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difference) relative to the reference are pivotal requirements.
Alignment and determination of differences in read pair place-
ments are directly affected by the accuracy of base-calling, by
read length, and by the capability to obtain sequence from
both ends of a genomic fragment. Maximizing read length and
obtaining paired end reads could ideally converge to provide
long reads across an entire fragment (and, by inference, to
provide haplotype information); but even so, the accuracy of
base-calling would determine the efficiency of re-sequencing
(including the required coverage of the genome needed),
which directly determines its cost. Base-calling accuracy is
influenced by the reaction chemistry and by the algorithms
developed to extract base-calls from raw data, among other
factors. In addition to these considerations, it is also necessary
to consider the ability of reaction chemistry and reaction con-
ditions to overcome any secondary-structure effects in the
templates that might truncate reads and affect coverage.
Current massively parallel sequencing
technologies 
So, are we anywhere near this lofty goal of the $1,000
genome? At present, the short answer is in fact ‘no’. Given
the level of interest in the goal, however, a significant
amount of activity and several innovative, interdisciplinary
technologies are now being pursued. I do not aim to describe
these new technologies in detail here; a recent review [14]
analyzes many of them comprehensively and comparatively.
Of such technologies, only one massively parallel sequencing
instrument, the GS-20 from 454 Life Sciences has so far
achieved commercial availability [15]. This instrument uses
pyrosequencing (the enzymatic sequencing method that
reports nucleotide incorporations using the reporter firefly
luciferase [16-18]), of genomic fragments that have been
captured and amplified on agarose beads to produce up to
20 Mb of sequencing data (in 100 base-pair read lengths)
per 4 hour instrument run. 
At its present base-calling accuracy, read length and cost per
run, a human genome cannot be sequenced for even
$100,000 using the 454 instrument, but it nevertheless rep-
resents an important first step toward the $1,000 genome
goal. Realistically, the 454 platform will continue to
improve, providing longer read lengths and higher base-
calling accuracy, and the commercial pressures of other
massively parallel instruments will drive down the costs per
run. The imminent entry of another massively parallel
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Figure 1
Comparison of conventional and massively parallel sequence pipelines. Both pipelines begin with a DNA fragmentation step. (a) The steps in a
conventional genome-sequencing pipeline, most of which require dedicated automation and processing in a 384-well format. DNA fragments are
subcloned into bacterial vectors and introduced into bacterial cells to prepare a library covering the whole genome. The transformed cells containing
subclones are plated and grown and then harvested by robotic picking, and the DNA from each one is isolated and sequenced. The sequence is visualized
by loading onto a capillary sequencing instrument. (b) The steps in a generic massively parallel genome-sequencing pipeline. Genomic DNA fragments
first undergo end repair to provide blunt ends for adaptor ligation and then have specific adaptors ligated to their ends that contain priming sites for PCR
and sequencing. The adaptor-ligated fragments are then hybridized to complementary adaptors that are fixed to a surface (a slide or bead), and then in
situ PCR amplification is used instead of bacterial amplification in vivo. Sequencing reactions of the surface-amplified fragments take place on the surface.
The sequence is visualized using either luciferase (pyrosequencing) or fluorescence reporting that is detected by a CCD camera.
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Amplification Sequencingplatform from Solexa Ltd, due this summer (2006), will help
to fuel this trend [14]. Others will follow in the ensuing
months and years. It is therefore conceivable that we are
quite close (within 1-2 years) to having instruments suitable
for the research laboratories that will provide the ‘discovery’
setting described earlier.
The challenges of having so much data 
If, for the sake of argument, we assume that novel, massively
parallel platforms will be developed and implemented to
rapidly and inexpensively re-sequence human genomes,
there are related concerns to point out. Namely, are the chal-
lenges posed by the enormous data-generation capabilities
and by the analysis of these data also being anticipated? The
tracking, storage and submission of the data from such plat-
forms will certainly pose significant challenges, even for
large sequencing centers. Similarly, intelligent algorithms
that use computing resources efficiently must be developed
for aligning and mapping re-sequencing data onto the refer-
ence genome, evaluating the aligned sequences for muta-
tions, indels, rearrangements, and so on, and reporting
genome-wide alterations in an annotated and organized
fashion. Most challenging of all, it will be of critical impor-
tance to develop meta-analyses and statistical analysis tools
that integrate across disparate data types, such as whole-
genome re-sequencing data, gene-expression data, copy-
number alterations, biochemical pathway information,
clinical parameters (age, sex, diagnosis and treatment), out-
comes, and so on, and thereby enable researchers to collec-
tively interpret these data for all samples in a study and to
form testable hypotheses from this discovery phase. These
bioinformatic challenges may well be as daunting as the
development of the instruments themselves, and ultimately
they will determine whether, once ready, the instruments
can be utilized immediately and effectively. 
Incorporating the new and ever-increasing functional
knowledge of the non-genic portions of the genome, which
often comes from incongruent sources, into meta-data
analyses will also determine whether we can make sense of
sequence changes that are found outside exons and known
regulatory regions. After all, the primary reason that current
PCR-based re-sequencing approaches typically focus on
exons is that the impact of a sequence change on an encoded
protein can be readily deciphered. Follow-on functional
studies of the altered protein can characterize the impact of a
mutation on function, can suggest other pathway-related
effects of the mutation, and ultimately may identify treat-
ments to counteract the mutation. It is at this interface -
where genome-scale sequence information and its conse-
quences begin to have an impact on clinical practice, direct-
ing treatment, indicating genetic predisposition to disease
and predicting outcomes - that applications of the $1,000
genome concept in a clinical context begin to take shape. But
first, much of the aforementioned discovery phase has to
take place. Without this, the contextual framework for
understanding an altered genome is not there.
Finally, once these discovery phases are completed for spe-
cific diseases, confirmed in thousands of affected individuals
and subjected to the rigor of approved clinical tests, they
must enter into the collective practice of medicine. Given
that this paradigm shift will require changes both in medical
education and in acceptance by health insurance providers
and ethicists [19], we have a long way to go. Even if we can
never comprehensively interpret the entirety of each re-
sequenced genome, the efforts under way to revolutionize
DNA sequencing, and to dramatically decrease its cost so
that multitudes of human genomes can be sequenced for dis-
covery and ultimately for clinical means, are well worth it.
Simply put, having this capability not only facilitates our
efforts to understand the genomic basis of disease, but also
opens our minds to questions not yet imagined. 
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